Yunnan Baiyao Group company profile
Company profile
Yunnan Baiyao Group has 9,286 employees and is headquartered in Kunming, China.
Sales of pharmaceuticals form the core of the business, with the company also distributing medicinal materials, health products and daily chemical goods across China. Its traditional Chinese medicine range for pain management and anti-inflammation includes the Yunnan Baiyao aerosol, ointment and band-aid, while its portfolio extends to generic drugs and specialty medicines for cardiovascular health, respiratory ailments, gynecology and pediatrics. The group also makes medical devices and tea products and offers pharmaceutical supply chain services.
In the fiscal year ended December 2025, revenue reached 41.2 billion yuan, an increase of 2.9% on the previous year, and net profit amounted to 5.2 billion yuan. At the end of that period the company had 9,286 employees. Its headquarters are in Kunming, China, where it was founded in 1902.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- China
- Headquarters
- No. 3686, Yunnan Baiyao Street, 650500, Kunming
- Employees
- 9,286
- Chief executive
- Ming Dong
- Founded
- 1902
- Fiscal year
- January - December
- Listing
- 000538 · SZSE
- Currency
- CNY
- ISIN
- CNE0000008X7
- Website
- yunnanbaiyao.com.cn
Yunnan Baiyao Group and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Yunnan Baiyao Group000538 | China | $15.07B | 9,286 | 11.2% | 19.4 |
| PharmaEssentia6446 | Taiwan | $15.94B | 131 | 38.4% | 74.1 |
| Laurus LabsLAURUSLABS | India | $14.13B | 7,059 | 24.1% | 97.8 |
| Shionogi4507 | Japan | $16.75B | 6,223 | 31.6% | 11.2 |
| Zydus LifesciencesZYDUSLIFE | India | $12.92B | 29,980 | 17.2% | 28.7 |
| CiplaCIPLA | India | $12.34B | 31,369 | 13.0% | 39.5 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
